{
    "clinical_study": {
        "@rank": "89010", 
        "arm_group": [
            {
                "arm_group_label": "SB4 and EU sourced Enbrel in Part A", 
                "arm_group_type": "Experimental", 
                "description": "SB4 followed by EU sourced Enbrel"
            }, 
            {
                "arm_group_label": "EU sourced Enbrel and SB4 in Part A", 
                "arm_group_type": "Experimental", 
                "description": "EU sourced Enbrel followed by SB4"
            }, 
            {
                "arm_group_label": "SB4 and US sourced Enbrel in Part B", 
                "arm_group_type": "Experimental", 
                "description": "SB4 followed by US sourced Enbrel"
            }, 
            {
                "arm_group_label": "US sourced Enbrel and SB4 in Part B", 
                "arm_group_type": "Experimental", 
                "description": "US sourced Enbrel followed by SB4"
            }, 
            {
                "arm_group_label": "EU and US sourced Enbrel in Part C", 
                "arm_group_type": "Other", 
                "description": "EU sourced Enbrel followed by US sourced Enbrel"
            }, 
            {
                "arm_group_label": "US and EU sourced Enbrel in Part C", 
                "arm_group_type": "Other", 
                "description": "US sourced Enbrel followed by EU sourced Enbrel"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetics, safety and immunogenicity of\n      SB4 and Enbrel (EU sourced Enbrel and US sourced Enbrel) in healthy male subjects."
        }, 
        "brief_title": "Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "-  Part A: Comparison between SB4 and EU sourced Enbrel\n\n        -  Part B: Comparison between SB4 and US sourced Enbrel\n\n        -  Part C: Comparison between EU sourced Enbrel and US sourced Enbrel"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects\n\n          -  Have a body weight between 60 and 94.9 kg and a body mass index between 20.0 and 29.9\n             kg/m\u00b2, inclusive.\n\n        Exclusion Criteria:\n\n          -  history and/or current presence of clinical significant atopic allergy,\n             hypersensitivity or allergic reactions, also including known or suspected clinically\n             relevant drug hypersensitivity to any components of the test and reference IP\n             formulation or comparable drugs.\n\n          -  active or latent Tuberculosis or who have a history of TB.\n\n          -  history of invasive systemic fungal infections or other opportunistic infections\n\n          -  systemic or local infection, a known risk for developing sepsis and/or known active\n             inflammatory process\n\n          -  serious infection associated with hospitalisation and/or which required intravenous\n             antibiotics\n\n          -  history of and/or current cardiac disease\n\n          -  have received live vaccine(s) within 30 days prior to Screening or who will require\n             live vaccine(s) between Screening and the final study visit.\n\n          -  Intake medication with a half-life > 24 h within 1 month or 10 half-lives of the\n             medication prior to the first administration of IP."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "138", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865552", 
            "org_study_id": "SB4-G11-NHV", 
            "secondary_id": "2012-004371-39"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SB4 and EU sourced Enbrel in Part A", 
                    "EU sourced Enbrel and SB4 in Part A", 
                    "SB4 and US sourced Enbrel in Part B", 
                    "US sourced Enbrel and SB4 in Part B"
                ], 
                "description": "SC administration", 
                "intervention_name": "SB4", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "SB4 and EU sourced Enbrel in Part A", 
                    "EU sourced Enbrel and SB4 in Part A", 
                    "EU and US sourced Enbrel in Part C", 
                    "US and EU sourced Enbrel in Part C"
                ], 
                "description": "SC administration", 
                "intervention_name": "EU sourced Enbrel", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "SB4 and US sourced Enbrel in Part B", 
                    "US sourced Enbrel and SB4 in Part B", 
                    "EU and US sourced Enbrel in Part C", 
                    "US and EU sourced Enbrel in Part C"
                ], 
                "description": "SC administration", 
                "intervention_name": "US sourced Enbrel", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacokinetics", 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Parexel International GmbH"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomised, Single-blind, Three-part, Two-period, Two-sequence, Single-dose, Cross-over Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Etanercept (SB4, EU Sourced Enbrel\u00ae and US Sourced Enbrel\u00ae) in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Parexel International GmbH", 
            "last_name": "Rainard Fuhr, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve from time zero to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Maximum serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Time to Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }
        ], 
        "source": "Samsung Bioepis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Bioepis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}